Published in Pain and Central Nervous System Week, November 18th, 2002
Adolor discovers, develops, and plans to commercialize proprietary pharmaceutical products for the treatment of pain and to mitigate certain of the side effects that are caused by current pain treatments. The company's lead product candidate, alvimopan, formerly known as ADL 8-2698, is being tested in phase III clinical studies for the management of opioid-induced bowel dysfunction and postoperative ileus. Adolor also has several novel proprietary compounds in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.